<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A nationwide survey of hematopoietic cell transplantation (HCT) was started in Japan in 1991, and the analyzed survey data have been presented as the annual report of the Japan Society for Hematopoietic Cell Transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>The 10-year overall survival (OS) rates after HCT for each disease are as follows: <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo>, 44.2%; <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 33.7%; adult T-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 24.6%; <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>, 53.3%; <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, 37.3%; non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 41.5%; Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 50.8%; <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, 72.5%; <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, 37.1%; <z:mpath ids='MPATH_310'>germ cell tumor</z:mpath>, 52.6%; and <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e>, 44.2% </plain></SENT>
<SENT sid="2" pm="."><plain>The 5-year OS rates for <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> and <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> were 40.6% and 23.6%, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Except in cord blood transplantation, engraftment was accomplished in more than 90% of patients </plain></SENT>
<SENT sid="4" pm="."><plain>The respective frequencies of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD were 41.1% and 34.9% for related bone marrow transplantation (BMT), 66.8% and 34.5% for unrelated BMT, 52.9% and 36.0% for allogeneic peripheral blood stem cell transplantation, and 53.3% and 32.1% for allogeneic cord blood transplantation </plain></SENT>
<SENT sid="5" pm="."><plain>OS for each disease was analyzed by patient age, stem cell source, donor type, disease status, and disease type </plain></SENT>
<SENT sid="6" pm="."><plain>These data provide objective and valuable information for hematologists as well as for patients who need HCT </plain></SENT>
</text></document>